As of 2025-12-28, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -3.81. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 351.22 mil USD. VNDA's TTM EBITDA according to its financial statements is -92.11 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 16.2x | 15.5x |
| Forward P/E multiples | 22.3x - 39.3x | 28.8x |
| Fair Price | (33.63) - (24.21) | (33.42) |
| Upside | -577.6% - -443.9% | -574.8% |
| Date | EV/EBITDA |
| 2025-12-23 | -3.68 |
| 2025-12-22 | -3.81 |
| 2025-12-19 | -3.63 |
| 2025-12-18 | -3.58 |
| 2025-12-17 | -3.67 |
| 2025-12-16 | -3.56 |
| 2025-12-15 | -3.55 |
| 2025-12-12 | -3.29 |
| 2025-12-11 | -3.53 |
| 2025-12-10 | -3.63 |
| 2025-12-09 | -3.18 |
| 2025-12-08 | -3.24 |
| 2025-12-05 | -2.75 |
| 2025-12-04 | -2.63 |
| 2025-12-03 | -2.68 |
| 2025-12-02 | -2.45 |
| 2025-12-01 | -2.52 |
| 2025-11-28 | -2.74 |
| 2025-11-26 | -2.70 |
| 2025-11-25 | -2.50 |
| 2025-11-24 | -2.43 |
| 2025-11-21 | -2.38 |
| 2025-11-20 | -2.40 |
| 2025-11-19 | -2.59 |
| 2025-11-18 | -2.73 |
| 2025-11-17 | -2.12 |
| 2025-11-14 | -2.09 |
| 2025-11-13 | -2.08 |
| 2025-11-12 | -2.13 |
| 2025-11-11 | -2.11 |
| 2025-11-10 | -2.13 |
| 2025-11-07 | -2.12 |
| 2025-11-06 | -2.13 |
| 2025-11-05 | -2.14 |
| 2025-11-04 | -2.09 |
| 2025-11-03 | -2.16 |
| 2025-10-31 | -2.09 |
| 2025-10-30 | -2.07 |
| 2025-10-29 | -2.77 |
| 2025-10-28 | -2.88 |
| 2025-10-27 | -2.90 |
| 2025-10-24 | -2.83 |
| 2025-10-23 | -2.82 |
| 2025-10-22 | -2.72 |
| 2025-10-21 | -2.69 |
| 2025-10-20 | -2.72 |
| 2025-10-17 | -2.68 |
| 2025-10-16 | -2.68 |
| 2025-10-15 | -2.75 |
| 2025-10-14 | -2.65 |